

Christopher H Van Dyck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8032884/publications.pdf>

Version: 2024-02-01

93
papers

4,768
citations

147566

31
h-index

102304

66
g-index

106
all docs

106
docs citations

106
times ranked

6311
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 111, 44-53.	1.5	25
2	Cerebral Volumetric Correlates of Apathy in Alzheimer's Disease and Cognitively Normal Older Adults: Meta-Analysis, Label-Based Review, and Study of an Independent Cohort. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1251-1265.	1.2	9
3	Emotion Processing Dysfunction in Alzheimer's Disease: An Overview of Behavioral Findings, Systems Neural Correlates, and Underlying Neural Biology. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2022, 37, 153331752210828.	0.9	12
4	Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [¹¹ C]UCB-J. <i>Alzheimer's and Dementia</i> , 2022, 18, 2527-2536.	0.4	55
5	Alzheimer disease neuropathology in a patient previously treated with aducanumab. <i>Acta Neuropathologica</i> , 2022, 144, 143-153.	3.9	18
6	Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 51-62.	0.6	29
7	Alzheimer's & Dementia: The Journal of the Alzheimer's Association. <i>Alzheimer's and Dementia</i> , 2021, 17, 316-317.	0.4	7
8	Association of A β 2 deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [¹¹ C]UCB-J. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 11.	3.0	53
9	Comparison of [¹¹ C]UCB-J and [¹⁸ F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2395-2409.	2.4	43
10	Amyloid-Associated Depression or Not?. <i>Biological Psychiatry</i> , 2021, 89, 737-738.	0.7	8
11	Pleiotropic effects of telomere length loci with brain morphology and brain tissue expression. <i>Human Molecular Genetics</i> , 2021, 30, 1360-1370.	1.4	4
12	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
13	Recruitment of a multi-site randomized controlled trial of aerobic exercise for older adults with amnesic mild cognitive impairment: The EXERT trial. <i>Alzheimer's and Dementia</i> , 2021, 17, 1808-1817.	0.4	5
14	Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysis. <i>NeuroImage</i> , 2021, 237, 118167.	2.1	18
15	Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [¹⁸ F]FPEB PET. <i>NeuroImage</i> , 2021, 238, 118217.	2.1	10
16	Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 1324.	4.5	51
17	Cognitive dysfunction and cerebral volumetric deficits in individuals with Alzheimer's disease, alcohol use disorder, and dual diagnosis. <i>Psychiatry Research - Neuroimaging</i> , 2021, 317, 111380.	0.9	8
18	Synaptic density is associated with cognitive performance in Alzheimer's disease: A PET imaging study with [¹¹ C]UCB-J. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
19	Subcellular localization of PDE4D and HCN1 in rhesus macaque entorhinal cortex layer II: Signature of vulnerability in Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e054671.	0.4	0
20	Classical complement cascade initiating C1q protein within neurons in the aged rhesus macaque dorsolateral prefrontal cortex. <i>Journal of Neuroinflammation</i> , 2020, 17, 8.	3.1	42
21	In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037791.	0.4	1
22	PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037792.	0.4	0
23	Solanezumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038028.	0.4	3
24	Gantenerumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038049.	0.4	2
25	ICA-derived sources of synaptic density PET ([¹¹ C]UCB) relate to cognitive impairment severity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041197.	0.4	3
26	Biochemical characterization of age-related calcium/cAMP/PKA signaling dysregulation and its effect on tau pathology in rhesus monkey cortex. <i>Alzheimer's and Dementia</i> , 2020, 16, e042017.	0.4	0
27	¹¹ C-PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043584.	0.4	0
28	Association between cerebral amyloid accumulation and synaptic density in Alzheimer's disease: A multitracer PET study. <i>Alzheimer's and Dementia</i> , 2020, 16, e043631.	0.4	0
29	Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044211.	0.4	2
30	Recruitment for a multi-site randomized controlled trial of aerobic exercise for older adults with amnesic mild cognitive impairment: The EXERT trial. <i>Alzheimer's and Dementia</i> , 2020, 16, e044658.	0.4	0
31	Validation of a simplified tissue-to-reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer's disease using [¹¹ C]UCB PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e045928.	0.4	1
32	The calcium-containing smooth endoplasmic reticulum is a focus of risk factors for early- and late-onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047651.	0.4	1
33	In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. <i>Alzheimer's and Dementia</i> , 2020, 16, 974-982.	0.4	170
34	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 21.	3.0	183
35	Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results. <i>PLoS ONE</i> , 2020, 15, e0229137.	1.1	61
36	PET imaging of mGluR5 in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 15.	3.0	29

#	ARTICLE	IF	CITATIONS
37	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
38	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
39	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
40	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
41	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
42	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
43	Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease. JAMA Neurology, 2019, 76, 1219.	4.5	107
44	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	1.2	84
45	Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. New England Journal of Medicine, 2019, 380, 1408-1420.	13.9	397
46	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. Brain, 2019, 142, 1063-1076.	3.7	122
47	P4â€481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCE. Alzheimer's and Dementia, 2019, 15, P1497.	0.4	0
48	ICâ€Pâ€140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTIâ€TRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P115.	0.4	0
49	ABBY. Neurology, 2018, 90, e1889-e1897.	1.5	188
50	Anti-Amyloid-Î² Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. Biological Psychiatry, 2018, 83, 311-319.	0.7	408
51	Cortical Î²-amyloid burden, gray matter, and memory in adults at varying APOE Î¼4 risk for Alzheimer's disease. Neurobiology of Aging, 2018, 61, 207-214.	1.5	28
52	The aged rhesus macaque manifests Braak stage III/IV Alzheimer's-like pathology. Alzheimer's and Dementia, 2018, 14, 680-691.	0.4	85
53	P2â€365: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P832.	0.4	0
54	P3â€088: THE AGING RHESUS MONKEY IS AN APPROPRIATE NEW ANIMAL MODEL FOR STUDYING THE ETIOLOGY AND TREATMENT OF TAU PATHOLOGY IN ASSOCIATION CORTEX. Alzheimer's and Dementia, 2018, 14, P1099.	0.4	0

#	ARTICLE	IF	CITATIONS
55	P1â€469: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P501.	0.4	1
56	ICâ€04â€03: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P8.	0.4	0
57	P4â€013: DESIGN OF A PHASEâ€3 TRIAL (APECS) TO EVALUATE THE BACE INHIBITOR VERUBECESTAT IN PRODROMAL AD. Alzheimer's and Dementia, 2018, 14, P1436.	0.4	0
58	P1â€274: A TARGETED MASSâ€SPECTROMETRY METHOD FOR QUANTIFICATION OF CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P387.	0.4	0
59	ICâ€Pâ€183: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P152.	0.4	0
60	Effects of Normative Adjustments to the Montreal Cognitive Assessment. American Journal of Geriatric Psychiatry, 2018, 26, 1258-1267.	0.6	29
61	Exploring Age-Related Changes in Resting State Functional Connectivity of the Amygdala: From Young to Middle Adulthood. Frontiers in Aging Neuroscience, 2018, 10, 209.	1.7	23
62	Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurology, 2018, 75, 1215.	4.5	304
63	Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial. Neurobiology of Aging, 2018, 70, 117-124.	1.5	15
64	Sleep Disturbance and the Risk of Cognitive Decline or Clinical Conversion in the ADNI Cohort. Dementia and Geriatric Cognitive Disorders, 2018, 45, 232-242.	0.7	20
65	Comparing three methods of computerised cognitive training for older adults with subclinical cognitive decline. Neuropsychological Rehabilitation, 2016, 26, 810-821.	1.0	62
66	P3-143: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first-degree relatives at varying ApoE4 risk for Alzheimer's disease. , 2015, 11, P680-P681.		0
67	IC-P-101: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first-degree relatives at varying ApoE4 risk for Alzheimer's disease. , 2015, 11, P69-P69.		0
68	<scp>F</scp>yn inhibition rescues established memory and synapse loss in <scp>A</scp>lzheimer mice. Annals of Neurology, 2015, 77, 953-971.	2.8	282
69	A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 35.	3.0	129
70	Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2014, 6, 213.	1.7	21
71	Fyn kinase inhibition as a novel therapy for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 8.	3.0	160
72	IC-P-108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. , 2014, 10, P60-P61.		0

#	ARTICLE	IF	CITATIONS
73	Cognitive and psychiatric effects of vitamin B12 replacement in dementia with low serum B12 levels: a nursing home study. <i>International Psychogeriatrics</i> , 2009, 21, 138.	0.6	17
74	Imaging Microglial Activation in Alzheimer's Disease: What Does It Mean?. <i>Biological Psychiatry</i> , 2008, 64, 833-834.	0.7	1
75	Striatal dopamine transporters correlate with simple reaction time in elderly subjects. <i>Neurobiology of Aging</i> , 2008, 29, 1237-1246.	1.5	35
76	A 24-week Randomized, Controlled Trial of Memantine in Patients With Moderate-to-severe Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2007, 21, 136-143.	0.6	155
77	A Responder Analysis of Memantine Treatment in Patients With Alzheimer Disease Maintained on Donepezil. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 428-437.	0.6	54
78	Striatal dopamine transporter availability with [¹²³ I]β-CIT SPECT is unrelated to gender or menstrual cycle. <i>Psychopharmacology</i> , 2005, 183, 181-189.	1.5	46
79	Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. <i>Journal of Nuclear Medicine</i> , 2005, 46, 745-51.	2.8	209
80	Central Serotonin Transporter Availability Measured With [¹²³ I]β-CIT SPECT in Relation to Serotonin Transporter Genotype. <i>American Journal of Psychiatry</i> , 2004, 161, 525-531.	4.0	122
81	Understanding the Latest Advances in Pharmacologic Interventions for Alzheimer's Disease. <i>CNS Spectrums</i> , 2004, 9, 24-28.	0.7	25
82	Unaltered Dopamine Transporter Availability in Adult Attention Deficit Hyperactivity Disorder. <i>American Journal of Psychiatry</i> , 2002, 159, 309-312.	4.0	127
83	Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. <i>American Journal of Geriatric Psychiatry</i> , 2002, 10, 36-43.	0.6	88
84	Neuroimaging in Alzheimer's disease: Relevance for treatment. <i>Current Psychiatry Reports</i> , 2001, 3, 13-19.	2.1	7
85	The Alpha-2A-Adrenoceptor Agonist, Guanfacine, Increases Regional Cerebral Blood Flow in Dorsolateral Prefrontal Cortex of Monkeys Performing a Spatial Working Memory Task. <i>Neuropsychopharmacology</i> , 2000, 23, 240-249.	2.8	131
86	Extended-Release Physostigmine in Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2000, 57, 157.	13.8	24
87	Age-related decline in central serotonin transporter availability with [¹²³ I]β-CIT SPECT. <i>Neurobiology of Aging</i> , 2000, 21, 497-501.	1.5	115
88	Equilibrium modeling of 5-HT _{2A} receptors with [¹⁸ F]deuterioaltanserin and PET: feasibility of a constant infusion paradigm. <i>Nuclear Medicine and Biology</i> , 2000, 27, 715-722.	0.3	18
89	Neuroimaging in Alzheimer's Disease: Relevance for the Development of Therapeutic Agents. <i>CNS Neuroscience & Therapeutics</i> , 2000, 6, 26-27.	4.0	0
90	Absence of an Apolipoprotein E ε4 Allele Is Associated With Increased Parietal Regional Cerebral Blood Flow Asymmetry in Alzheimer Disease. <i>Archives of Neurology</i> , 1998, 55, 1460.	4.9	30

#	ARTICLE	IF	CITATIONS
91	The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease. <i>Psychopharmacology</i> , 1997, 132, 217-226.	1.5	24
92	Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. <i>American Journal of Medical Genetics Part A</i> , 1997, 74, 497-500.	2.4	24
93	Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. , 1997, 74, 497.		1